🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ABBV-400 a new antiMET ADC tested in pretreated EGFRm NSCLC reported ORR 26% and DoR 9.8 regardless cMET expression. It is a crowded space with BL-B01D1, DB-1310, dual TKI EGFR/ET etc. Can we ⬆️ ABBV-400 combining with osimertinib?TelisoV + Osi > Teliso alone in mEGFR 🫁#ASCO25

1L Olomorasib (G12Ci) + pembro in NSCLC ORR ✅ ITT 74% ✅ PD-L1 hi 90% 12m PFS ✅ ITT 67% ✅ PD-L1 hi 60% Gr3+ AE 22% ⬆️ AST/ALT, manageable 8% diarrhoea 🤔 ➡️ Ph3 SUNRAY 🤔 Better activity & AE than 1st gen G12Ci 🤔 1L combo 2nd gen G12Ci = the future #LCSM #ASCO25

CM-816: Final OS Update ✅ ⬆️ mOS NR v 73m, HR 0.72 ✅ Most benefit in PD-L1 +ve ✅ ⬆️ 5yr EFS 49% v 34% ✅ 95% 5yr EFS if pCR ✅ ⬆️ OS with ctDNA clearance 💭 Confirms activity of this combination 💭 KN671 becoming more popular in 🇬🇧 #LCSM #ASCO25

NeoADAURA, Osi/osi-chemo/chemo neoadj 2 vs 8% PD rate MPR 26 vs 25 vs 2%: benefit across genotype & stage. Greater depth response by osi-chemo>osi Nodal downstaging in both osi arms Osi/osi-chemo reduces PD, gets MPR Impressive EFS by MPR vs not #ASCO25

#ASCO25 SWOG/NRG S1914: Ph III atezo + SBRT vs SBRT high-risk early-stage NSCLC- negative ⚠️ IO + SBRT still challenging 🤔Current gaps: Duration? Concurrent/ seq? Who benefit? 📊 Not read out: PACIFIC-4 (IO 2y) ✅ I-SABR (IO 6mo) ❌ KEYNOTE-867 (IO 1y) ❌ S1914 (2y)

Dr Gronberg presents consolidation atezo 1yr post cCRT vs observation RP3 trial in LS-SCLC, PS2 allowed (8.2%), stage 1-3. 1o OS. N=216, N170 randomized. 27% Discont for AEs PFS HR 0.89 neg; OS HR 1.14 negative So, Durva remains SoC for this indication #ASCO25

❌ Atezolizumab after chemoRT, LS-SCLC ❗️⬆️ 3+ AEs ❌ No PFS or OS benefit 🔺Only 35% completed 1yr Atezo ❓ slight benefit in men & with carboplatin 🤔 Compare to +ve ADRIATIC #LCSM #ASCO25

IMforte: lurbinectedin + atezo maintenance ES-SCLC ✅ ⬆️ mPFS 5.4 v 2.1m, HR 0.54 ✅ ⬆️ mOS 13.2 v 10.6m, HR 0.73 ✅ ⬆️ ORR 19% v 10% 🔺Gr3+ AE 25% v 5% 🔺 Myelosupression, N&V, fatigue 🤔 Active combo, at cost of toxicity 🤔 OS impressive = 16m from diagnosis #LCSM #ASCO25

DeLLphi-304: Ph3 Tarlatamab in 2L+ ES-SCLC 👉 44% <90d platinum TFI ✅ ⬆️ OS 13.6 v 8.3m HR 0.60 ✅ ⬆️ PFS HR 0.71; ⬆️ ORR 35 v 20% ✅ ⬆️ PROs AE: CRS & ICONs challenging 🤔 = Standard of care 🤔 Complex to give & monitor 🤔 Need 🇬🇧 access #LCSM #ASCO25

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/

#ASCO25 Developmental Therapeutics CSS🔥 Another presentation on timing of chemo-IO, this time a large observational study of early (<11:30am) v late (>11:30am) IO: - early assoc with benefit in PFS & OS - OS HR 0.49 - pooled cohort of >700pts from 🇨🇳+🇫🇷 ASCO OncoAlert

Give it up for Eric K. Singhi, MD (Eric K. Singhi, MD), of MD Anderson Cancer Center, who will be taking over OncLive's Twitter and Instagram today at #ASCO25! 👏😌 Follow along for ✨exclusive✨ photos and videos on the ground at the meeting! #LCSM #ASCO #CancerResearch

BTOG The ICR The Royal Marsden NHS Foundation Trust Tom Newsom-Davis Dr Riyaz Shah

Real-world data on 1323 EGFR+ NSCLC pts on 1L osimertinib: • Median OS: 28.6 mo • High-risk pts:  - TP53: 25.7  - Brain mets: 24.3  - Liver mets: 19.3  - ECOG ≥2: 18.1 This isn’t good enough. Patients & families deserve more. sciencedirect.com/science/articl…

Big results from ASCO 2025 – but what’s relevant for UK practice? Join our expert webinar for a concise review of the data that matters in thoracic oncology. ✅ Member-exclusive 🔗 btog.org/asco-update-we… #LCSM #OncTwitter #ASCO25 #LungCancer #BTOGASCO2025Webinar

👀 Looking forward to BTOG ASCO 2025 update 📆 Monday 16th June, 6.30pm 🎥 Webinar. See btog.org to register 💰 Don’t be silly! It’s free! 👥 Featuring an all star cast 👇 👊👊

Now that Taletrectinib is approved by @usfda for metastatic NSCLC Check out the comparison of data for three ROS-1 inhibitors, entrectinib , repotrectinib and Taletrectinib. Useful for quick summary of data for all 3 . Rami Manochakian MD, FASCO Cancer Education OncoAlert Oncology Brothers Kate Sears

Disappointing that Repotrectinib is unlicensed in 🇬🇧, and hence no application for NICE approval So not available for 🇬🇧 patients, despite the evidence of efficacy May not be great commercial priority, but is of great clinical value to our patients ROS1DERS UK The ROS1ders, Inc.

🧬 CAR-T, liquid biopsy, AI in lung cancer - #ASCO25 delivered major developments. 📣 Get the expert take on what’s practice-changing for the UK. 📅 Mon 16 June | Free webinar for BTOG members btog.org/asco-update-we… #LCSM #LungCancer #BTOGASCO2025Webinar Tom Newsom-Davis

Great start to the #UKOF25 Treating the older patient with cancer session with Etienne Brain Young SIOG